Loading...
Market
What will be the outcome of the Phase 1 clinical trial results for a vaccine using Stanford's nanoparticle adjuvant by June 30, 2025?
2
Resolution / Starting Odds
Positive • 25%
Negative • 25%
Mixed • 25%
Not published • 25%
Peer-reviewed journals and ClinicalTrials.gov
Story
Stanford Develops Nanoparticle Adjuvant for Robust, Tunable Vaccine Immune Response
Aug 7, 2024, 06:41 PM
Researchers at Stanford Engineering have developed a new nanoparticle adjuvant that enhances the effectiveness of vaccines by producing more robust, longer-lasting, and tunable immune responses. This advancement, detailed in Science Advances, builds on existing vaccine additives and offers promising improvements in vaccine efficacy. The work by Ou Ben and Julie Baillet is part of ongoing efforts to improve vaccine performance, particularly in the context of COVID-19 and other diseases.
View original story
Similar markets
Effective • 25%
Moderately Effective • 25%
Ineffective • 25%
Halted • 25%
Successful • 25%
Partially successful • 25%
Unsuccessful • 25%
No results announced • 25%
Safety concerns resolved • 25%
Further investigation required • 25%
Vaccine trials permanently halted • 25%
Other outcome • 25%
Significant tumor shrinkage • 25%
Improved survival rates • 25%
No significant effect • 25%
Other • 25%
Successful with no major side effects • 25%
Successful with some side effects • 25%
Unsuccessful • 25%
Inconclusive • 25%
Positive results • 25%
Negative results • 25%
Mixed results • 25%
No results announced • 25%
Significant improvement • 25%
Moderate improvement • 25%
No improvement • 25%
Worsening condition • 25%
Significant reduction in HIV levels (over 1000-fold) • 25%
Moderate reduction in HIV levels (100-1000 fold) • 25%
Minimal reduction in HIV levels (less than 100 fold) • 25%
No significant reduction in HIV levels • 25%
Exceeds regulatory criteria • 25%
Meets regulatory criteria • 25%
Fails to meet regulatory criteria • 25%
Trial delayed or inconclusive • 25%
Complete Response • 25%
Partial Response • 25%
Stable Disease • 25%
Progressive Disease • 25%
Full approval • 25%
Emergency use authorization • 25%
Conditional approval • 25%
No approval • 25%
Highly effective • 25%
Moderately effective • 25%
Slightly effective • 25%
Ineffective • 25%